Industry update from Biotech Showcase.
Almost 16min
AML and Glioblastoma are both orphan disease's.
Orphan gene (he throws in cell) therapies are 3.5 times more likely to be approved once entering phase 1 trials than average drugs included in BIO's global trends in R&D 2023 report.
- 48% higher success rate in phase 1 clinical trials.
- 65% higher success rate in phase 2 clinical trials.
- 30% higher success rate in phase 3 clinical trials.
I dare say our early positive data puts us even higher.
- Forums
- ASX - By Stock
- Ann: ADVENT-AML Phase 1B clinical trial open to enrolment
Industry update from Biotech Showcase. Almost 16minAML and...
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.7¢ |
Change
-0.002(10.5%) |
Mkt cap ! $15.52M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.7¢ | $39.38K | 2.206M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 500356 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 1425000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 500356 | 0.017 |
6 | 597631 | 0.016 |
7 | 695169 | 0.015 |
3 | 2499999 | 0.014 |
1 | 200000 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 1425000 | 3 |
0.019 | 385211 | 4 |
0.020 | 285200 | 3 |
0.021 | 1054169 | 3 |
0.022 | 200000 | 1 |
Last trade - 14.17pm 04/06/2024 (20 minute delay) ? |
|
|||||
Last
1.8¢ |
  |
Change
-0.002 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
1.7¢ | 1.8¢ | 1.7¢ | 435334 | ||
Last updated 13.53pm 04/06/2024 ? |
Featured News
CHM (ASX) Chart |